Trinity Biotech (TRIB) Total Current Liabilities (2009 - 2025)

Trinity Biotech's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $141.2 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 339.97% year-over-year to $141.2 million; the TTM figure through Dec 2025 stood at $141.2 million (up 339.97% YoY), while the FY2025 annual figure was $141.2 million, up 339.97% from the prior year.
• Total Current Liabilities came in at $141.2 million for Q4 2025 at Trinity Biotech, up from $31.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $141.2 million in Q4 2025 to a low of $12.7 million in Q3 2023.
• A 5-year average of $41.3 million and a median of $24.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 364.27% in 2021 and tumbled 86.86% in 2022, its largest moves.
• Trinity Biotech's Total Current Liabilities stood at $100.5 million in 2021, then slumped by 82.75% to $17.3 million in 2022, then decreased by 13.29% to $15.0 million in 2023, then jumped by 113.47% to $32.1 million in 2024, then surged by 339.97% to $141.2 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $141.2 million, $31.5 million, and $32.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison